[Edaily Reporter Minji Son ] As July began (June 29–July 3), the pharmaceutical and biotech industries turned their attention to Celltrion Pharm Inc.’s large-scale investment in production facilities and AriBio’s successful fundraising. It appears that domestic biotech companies are now moving in earnest to achieve scale growth and expand their business foundations through strengthened production capabilities and the expansion of global partnerships.

Celltrion Pharm Inc. to Invest 2 Trillion Won in PFS Production Facility Construction

Celltrion Pharm Inc. has drawn attention by unveiling a large-scale investment plan to expand its PFS (Pre-filled Syringe) production capacity.

According to the Financial Supervisory Service’s electronic disclosure system on the 2nd, Celltrion Pharm Inc. announced plans to invest 2 trillion won to build a PFS production facility in North Chungcheong Province to meet growing global demand for PFS. The company plans to invest 1 trillion won between 2028 and 2032 to construct the first phase of the new production facility, and will proceed with a second-phase investment of 1 trillion won to build additional production facilities, taking global demand into account.

PFS is a dosage form in which medication is pre-filled and supplied. Since it eliminates the need to transfer medication from a separate vial (a glass container for pharmaceuticals), it enhances patient convenience and safety while reducing the dispensing burden on healthcare professionals. Recently, as the market for self-injectable medications—such as obesity treatments and therapies for autoimmune diseases—has grown rapidly, demand for PFS has also been expanding significantly.

Since PFS production requires highly sterile processes and precision filling technology on the production line, demand has largely relied on imports until now. However, Celltrion Pharm Inc. has already supplied 20 million syringes of PFS domestically and internationally, and once this new production facility is completed, an additional 50 million syringes will be added, bringing the total production capacity to 70 million syringes.

Celltrion Pharm Inc. already operates production facilities for synthetic and biopharmaceuticals in Cheongju and Jincheon. With the addition of this large-scale in-house production facility, the company is expected to further enhance its global supply competitiveness by integrating it with its existing facilities.

Aribio Secures 42.5 Billion Won from Fuxing Pharmaceutical… Expectations for Long-Term Cooperation Rise

AriBio has secured a strategic equity investment totaling 42.5 billion won ($27.5 million) from China’s Fuxing Pharmaceutical. This equity investment follows a global exclusive licensing agreement signed in May for “AR1001,” which is being developed as the world’s first oral disease-modifying therapy (DMT) for Alzheimer’s disease.

Under the agreement, Fuxing Pharmaceutical will first invest 11.5 billion won ($7.5 million) as an initial investment, followed by a second investment of 31 billion won ($20 million). Upon completion of this investment, Fuxing Pharmaceutical will become AriBio’s third-largest shareholder, following Solux Co., Ltd. (scheduled to change its name to AriBio Holdings) and SamjinPharmaceutical.

This equity investment suggests that the two companies are expanding their relationship beyond a single technology export to a long-term partnership. While technology export agreements typically focus on the transfer of rights and milestone payments, the fact that the counterparty has gone so far as to make a direct equity investment reflects a commitment to jointly pursue the entire process—from future development to commercialization.

Meanwhile, the domestic biotech industry assesses that contractual relationships are becoming more multifaceted, moving beyond simple global technology transfers, as seen in the case of AriBio. While in the past, domestic biotech companies often limited their involvement to transferring candidate compounds and receiving upfront payments and milestone payments, there has recently been an increase in cases where counterparties participate in equity investments or collaborate all the way through production and commercialization. A prime example is ABL Bio Inc., which recently signed a 4 trillion won technology transfer agreement with Eli Lilly and subsequently secured a strategic equity investment of approximately 22 billion won ($15 million).